MX344543B - Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. - Google Patents

Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.

Info

Publication number
MX344543B
MX344543B MX2012008730A MX2012008730A MX344543B MX 344543 B MX344543 B MX 344543B MX 2012008730 A MX2012008730 A MX 2012008730A MX 2012008730 A MX2012008730 A MX 2012008730A MX 344543 B MX344543 B MX 344543B
Authority
MX
Mexico
Prior art keywords
prognosis
diagnosis
compositions
treatment
methods
Prior art date
Application number
MX2012008730A
Other languages
English (en)
Other versions
MX2012008730A (es
Inventor
Schwartz David
Seibold Max
Original Assignee
Nat Jewish Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Health filed Critical Nat Jewish Health
Publication of MX2012008730A publication Critical patent/MX2012008730A/es
Publication of MX344543B publication Critical patent/MX344543B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a diagnóstico y terapéuticos para enfermedad pulmonar, en particular, enfermedad de pulmón fibrótico. Los inventores han encontrado que un gen MUC5B de variante genética está asociado con la expresión incrementada del gen, el riesgo incrementado de desarrollar una enfermedad pulmonar, y una prognosis mejorada y supervivencia entre aquellos que desarrollan la enfermedad pulmonar.
MX2012008730A 2010-01-26 2011-01-26 Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares. MX344543B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29847310P 2010-01-26 2010-01-26
US29881410P 2010-01-27 2010-01-27
US32323810P 2010-04-12 2010-04-12
US32376010P 2010-04-13 2010-04-13
PCT/US2011/022621 WO2011094345A1 (en) 2010-01-26 2011-01-26 Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders

Publications (2)

Publication Number Publication Date
MX2012008730A MX2012008730A (es) 2012-12-17
MX344543B true MX344543B (es) 2016-12-19

Family

ID=44319751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008730A MX344543B (es) 2010-01-26 2011-01-26 Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.

Country Status (10)

Country Link
US (6) US8673565B2 (es)
EP (1) EP2529033B1 (es)
CA (2) CA3101636A1 (es)
DK (1) DK2529033T3 (es)
ES (1) ES2636671T3 (es)
HU (1) HUE033044T2 (es)
MX (1) MX344543B (es)
PL (1) PL2529033T3 (es)
SI (1) SI2529033T1 (es)
WO (1) WO2011094345A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129934A2 (en) 2009-05-07 2010-11-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
CA3101636A1 (en) 2010-01-26 2011-08-04 National Jewish Health Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter
ES2660113T3 (es) * 2011-12-21 2018-03-20 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Procedimientos relacionados con la fibrosis pulmonar idiopática (FPI)
WO2014121180A1 (en) * 2013-02-01 2014-08-07 The University Of Chicago Genetic variants in interstitial lung disease subjects
RU2670148C2 (ru) * 2013-02-14 2018-10-18 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо Способы прогнозирования риска интерстициальной пневмонии
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2971128B1 (en) * 2013-03-15 2023-03-01 Veracyte, Inc. Biomarkers for diagnosis of lung diseases and methods of use thereof
JP6141160B2 (ja) 2013-09-25 2017-06-07 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子およびその動作方法、並びに電子機器およびその動作方法
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10543185B2 (en) 2015-04-22 2020-01-28 The University Of Chicago Method for treating idiopathic pulmonary fibrosis
US20200171024A1 (en) 2017-06-26 2020-06-04 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for the diagnosis and treatment of fibrotic lung disease
WO2021142245A1 (en) * 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
WO2022087329A1 (en) * 2020-10-23 2022-04-28 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
IL313088A (en) * 2021-12-09 2024-07-01 Splisense Ltd Oligonucleotides against MUC5AC and methods for modulating the expression of MUCIN

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
DE69830395T2 (de) * 1997-03-20 2006-01-26 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Iterative resequenzierung
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2005520479A (ja) * 2000-05-09 2005-07-14 ジェネティクス インスティテュート，エルエルシー 乾癬の確認、評価、予防および治療のための組成物、キットおよび方法
EP1354038A2 (en) 2000-12-28 2003-10-22 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20030040009A1 (en) * 2001-08-14 2003-02-27 University Of Southern California Saliva-based methods for preventing and assessing the risk of diseases
US6818446B2 (en) * 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
AU2002950878A0 (en) * 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
US7300788B2 (en) * 2002-10-08 2007-11-27 Affymetrix, Inc. Method for genotyping polymorphisms in humans
US20070202109A1 (en) * 2003-09-24 2007-08-30 Oncotherapy Science, Inc. Method Of Diagnosing Breast Cancer
US20050125851A1 (en) * 2003-12-09 2005-06-09 Children's Hospital Research Foundation Methods of diagnosis and treatment of interstitial lung disease
JP4825956B2 (ja) 2004-05-19 2011-11-30 財団法人ヒューマンサイエンス振興財団 気道粘膜炎症性疾患の罹患リスクの判定
EP1888777A4 (en) * 2005-05-19 2008-11-26 Synergenz Bioscience Ltd METHODS AND COMPOSITIONS FOR EVALUATING FUNCTIONS AND PULMONARY DISORDERS
EP2074224A4 (en) * 2006-10-17 2010-07-21 Synergenz Bioscience Ltd METHOD AND COMPOSITIONS FOR ASSESSING LUNG FUNCTION AND LUNG RIDING
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US20120094842A1 (en) * 2007-11-01 2012-04-19 Peter Durie Methods of assessing and treating pulmonary disease
WO2009073167A2 (en) 2007-12-03 2009-06-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions
WO2009140715A1 (en) 2008-05-21 2009-11-26 Central Northern Adelaide Health Service Diagnostic method
DE112010002991A5 (de) 2009-07-20 2012-11-29 Sigismund Laskowski Trageverpackung zur Aufnahme von Behältnissen
CA3101636A1 (en) 2010-01-26 2011-08-04 National Jewish Health Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter

Also Published As

Publication number Publication date
US20190040467A1 (en) 2019-02-07
US11649503B2 (en) 2023-05-16
DK2529033T3 (en) 2017-08-07
WO2011094345A1 (en) 2011-08-04
EP2529033B1 (en) 2017-05-24
CA2787994C (en) 2021-01-12
PL2529033T3 (pl) 2017-10-31
CA3101636A1 (en) 2011-08-04
CA2787994A1 (en) 2011-08-04
US20140220570A1 (en) 2014-08-07
MX2012008730A (es) 2012-12-17
ES2636671T3 (es) 2017-10-06
US10858707B2 (en) 2020-12-08
US20230313307A1 (en) 2023-10-05
US20110217315A1 (en) 2011-09-08
EP2529033A4 (en) 2013-07-17
US20170183730A1 (en) 2017-06-29
SI2529033T1 (sl) 2017-08-31
US20210198738A1 (en) 2021-07-01
HUE033044T2 (hu) 2017-11-28
EP2529033A1 (en) 2012-12-05
US8673565B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
MX2012008730A (es) Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
TN2013000412A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
UA115540C2 (uk) Антитіло до il-36r
EP2539470A4 (en) METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
MX2013008367A (es) Firmas de esxpresion genetica de cancer de colon y metodos de uso.
WO2012038068A3 (en) Means and methods for the prediction of treatment response of a cancer patient
MX2015004844A (es) Firmas geneticas de trastornos inflamatorios que se relacionan con el higado.
WO2012093821A3 (ko) 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
AU2018290809A1 (en) Biomarkers for the diagnosis and treatment of fibrotic lung disease
EA201792669A1 (ru) Igfbp3 и его применение
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
WO2010144846A3 (en) Gastrointestinal disease or disorder imaging and treatment
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
MX343803B (es) Complejo de ipp como marcador para tratamiento de erlotinib.

Legal Events

Date Code Title Description
FG Grant or registration